Investigating how new antiherpesviral drugs affect the placenta
Human placental biodisposition of novel antiherpesviral drugs, amenamevir and pritelivir, using ex vivo and in vitro experimental models
This study is looking at how two new medications for treating genital herpes, amenamevir and pritelivir, affect the placenta during pregnancy to make sure they are safe for both moms and their babies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Med Br Galveston NIH-funded |
| Lab location | 1 site (Galveston, United States) |
| Project ID | NIH-10895969 on NIH RePORTER |
What this research studies
This research explores the effects of two novel antiherpesviral drugs, amenamevir and pritelivir, on the human placenta. By using advanced laboratory techniques, the study aims to understand how these medications are processed by the placenta, which is crucial for ensuring the safety of pregnant women and their babies. The research will involve both ex vivo and in vitro models to simulate the conditions of the human placenta and assess the potential risks and benefits of these drugs during pregnancy. The ultimate goal is to gather important data that could support the use of these drugs in treating genital herpes in pregnant women.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant women who are infected with genital herpes and are seeking treatment options.
Not a fit: Patients who are not pregnant or those who do not have genital herpes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer treatment options for pregnant women with genital herpes, reducing the risk of transmission to their newborns.
How similar studies have performed: Previous research has shown promise with similar approaches in evaluating the safety and efficacy of new antiviral treatments, indicating potential for success in this area.
Where this research is happening
Galveston, United States
- University of Texas Med Br Galveston — Galveston, United States (Active)
Researchers
- Principal investigator: Bryant, Valentina Fokina — University of Texas Med Br Galveston
- Study coordinator: Bryant, Valentina Fokina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.